tbuckley/cabot-search huggingface dataset:
HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors
Authors: Mikolaj Medon, Eva Vidacs, Stephin J Vervoort, Jason Li, Misty R. Jenkins, Kelly M. Ramsbottom, Joseph A. Trapani, Mark J. Smyth, Phillip K. Darcy, Peter W. Atadja, Michael A. Henderson, Ricky W. Johnstone, Nicole M. Haynes
Journal: Cancer Research (2017)

Histone deacetylase inhibitors (HDACi) may engage host immunity as one basis for their antitumor effects. Herein, we demonstrate an application of this concept using the HDACi panobinostat to augment the antitumor efficacy of trastuzumab (anti-HER2) therapy, through both tumor cell autonomous and nonautonomous mechanisms. In HER2+ tumors that are inherently sensitive to the cytostatic effects of trastuzumab, cotreatment with panobinostat abrogated AKT signaling and triggered tumor regression in mice that lacked innate and/or adaptive immune effector cells. However, the cooperative ability of panobinostat and trastuzumab to harness host anticancer immune defenses was essential for their curative activity in trastuzumab-refractory HER2+ tumors. In trastuzumab-resistant HER2+ AU565pv xenografts and BT474 tumors expressing constitutively active AKT, panobinostat enhanced the antibody-dependent cell-mediated cytotoxicity function of trastuzumab. IFNγ-mediated, CXCR3-dependent increases in tumor-associated NK cells underpinned the combined curative activity of panobinostat and trastuzumab in these tumors. These data highlight the immune-enhancing effects of panobinostat and provide compelling evidence that this HDACi can license trastuzumab to evoke NK-cell-mediated responses capable of eradicating trastuzumab-refractory HER2+ tumors. Cancer Res; 77(10); 2594-606. ©2017 AACR.
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Ashraf Z Badros, Elizabeth Hyjek, Ning Ma, Alexander M. Lesokhin, Aaron P. Rapoport, Mehmet H. Kocoglu, Emily Lederer, Sunita Philip, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, Zeba Singh
Journal: Blood (2016)
Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes
Authors: Tongzhi Wu, Laurence G. Trahair, Tanya J. Little, Michelle J. Bound, Xiang Zhang, Hang Wu, Zilin Sun, Michael Horowitz, Christopher K. Rayner, Karen L. Jones
Journal: Diabetes Care (2017)

OBJECTIVE To evaluate effects of vildagliptin and metformin on blood pressure (BP) and heart rate (HR) responses to intraduodenal (ID) glucose in diet-controlled type 2 diabetes. RESEARCH DESIGN AND METHODS Study A compared vildagliptin (50 mg) and placebo, given 60 min before a 120-min ID glucose infusion at 2 or 4 kcal/min (ID2 or ID4) in 16 patients. Study B compared metformin (850 mg) and placebo, given 30 min before ID2 over 120 min in 9 patients. RESULTS Systolic (P = 0.002) and diastolic (P &amp;lt; 0.001) BP were lower and HR greater (P = 0.005) after vildagliptin compared with placebo, without interaction between vildagliptin and the glucose infusion rate. In contrast, HR was greater after metformin than placebo (P &amp;lt; 0.001), without any difference in systolic or diastolic BP. CONCLUSIONS Vildagliptin reduces BP and increases HR, whereas metformin increases HR without affecting BP during ID glucose infusion in type 2 diabetes. These distinct cardiovascular profiles during enteral nutrient exposure may have implications for postprandial hypotension.
Sessile Serrated Polyps and Colorectal Cancer—Reply
Authors: David Lieberman
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhibition of Mitochondrial Translation As a Therapeutic Strategy for Acute Myeloid Leukemia (AML)
Authors: Marko Skrtic, Shrivani Sriskanthadevan, Bozhena Livak, Marinella Gebbia, Xiaoming Wang, Zezhou Wang, Rose Hurren, Yulia Jitkova, Marcela Gronda, Neil Maclean, Courteney Lai, Yanina Eberhard, Justyna Bartoszko, Paul A. Spagnuolo, Angela Rutledge, Alessandro Datti, Troy Ketela, Jason Moffat, Brian H Robinson, Jessie M Cameron, Jeff L. Wrana, Connie J. Eaves, Mark D. Minden, Jean C.Y. Wang, John E. Dick, R. Keith Humphries, Corey Nislow, Guri Giaever, Aaron D Schimmer
Journal: Blood (2011)
Abstract P5-10-01: Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography
Authors: T Ali-Shaw, WA Ueng, MS Trivedi, H Yi, RR David, A Vanegas, JM Vargas, R Sandoval, J Wood, R Kukafka, KD Crew
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
IgG4-Related Lymphadenopathy: a Distinct Clinicopathological Entity That Is Associated with IgG4-Related Sclerosing Diseases
Authors: Yayoi Fujiwara, Kenji Notohara, Yasuyuki Arai, Takahito Kawata, Takeshi Ito, Satoko Morita, Takeshi Maeda, Tatsuhito Onishi, Chisato Mizutani, Fumio Matsuyama, Yasunori Ueda, Kaori Uchino, Yoji Wani, Choutatsu Tsukayama
Journal: Blood (2008)
Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)
Authors: Issa F. Khouri, Elias Jabbour, Rima M Saliba, Celina Ledesma, Jan A Burger, Susan O'Brien, Alison M Gulbis
Journal: Blood (2015)
Pluripotent SSEA-1+ OCT-4+ CXCR4+ Sca-1+ lin− CD45− Very Small Embryonic Like (VSEL) Stem Cells Reside in Multiple Murine Organs - Are VSEL Epiblast-Derived Functional Pluripotent Precursors for Tissue Committed Stem Cells or Merely Quesiscent Remants from Embryonic Development?.
Authors: Magda Kucia, Ewa K. Zuba, Wu Wan, Boguslaw Machalinski, Wojtek Wojakowski, Mariusz Ratajczak
Journal: Blood (2007)
OP23. T CELL EXPRESSION IN CNS LYMPHOMAS: A SINGLE CENTRE EXPERIENCE OF PRIMARY CNS T-CELL LYMPHOMAS
Authors: Ms Beverly Cheserem, Mr Ravindran Visagan, Mr Simon Stapleton, Dr Leslie Bridges, Mr George Eralil
Journal: Neuro-Oncology (2017)

INTRODUCTION: Primary CNS lymphomas (PCNSLs) are a rare entity and comprise only 5% of brain tumours. Histopathologically they are primarily of B-cell phenotype. Primary CNS T-Cell Lymphomas (PCNSTLs) constitute <5% of all PCNSLs. Such rarity in clinical practice means there is a paucity of robust data on the long term outcomes for patients with PCNSTLs. We report our PCNSTL (or T-Cell rich PCNSLs) experience over 7 years. METHODS: We reviewed our pathology database for all PCNSLs diagnosed between 2009 and 2016. Specifically T-cell expression, Ki67 Proliferative Index (KPI) and CD expression were looked reviewed from histopathological reports. Treatment options, survival and complications were also reviewed. RESULTS: We identified a total of 58 PCNSLs of which 2 were pure T-cell lymphomas and 3 were B cell lymphomas with T cell expression (2 were ‘T-cell rich’; 1 was anaplastic). Mean age was 58.4 (44–66 years). These 5 patients comprised of 4 males and 1 female. One patient was HIV positive; and another had a previous history of lung cancer. On FLAIR MR Imaging, three patients had supratentorial bihemispheric lesions; and one patient (who is still alive) had a left cerebellar lesion. In our small sample, those with bihemispheric lesions had shorter survival times which would correlate with extent of disease dissemination within the white matter tracts. The 2 ‘T-cell rich’ samples had a KPI of 70–80%. (In the PCNSLs with T cell expression, the KPI ranged from 20% - 90% and in our group this correlated with survival).One patient whose cells demonstrated a KPI of 90% survived for only 56 days from diagnostic biopsy. Immunohistochemistry showed variable CD expression (as in previous published literature). All 5 patients had their histology dually reported by a neuropathologist and haemotopathologist. One patient was not fit enough for oncology treatment. The other 4 had chemotherapy and all had relapses or progression on treatment. Mean survival time was 275.2 days (7.56months with a range of 56–571 days). At the time of writing, 1 patient was still alive with ongoing haematology clinic review; 1 was discharged to a palliative care facility and 3 patients had died. SUMMARY: With PCNSTls or PCNSLs with T-cell expression, there seems to be an association between survival and the Ki67 proliferative index in addition to presence of bilateral supratentorial disease on MR imaging. As they are extremely rare presentations, further studies would perhaps benefit from multi-centre involvement. Their histological diagnosis (especially immunohistochemistry) remains challenging due to the heterogeneity of the cells and CD expression, and in our experience has often required multiple histology reviews.
Pre-exposure prophylaxis for infants exposed to HIV through breast feeding
Authors: Philippe Van de Perre, Chipepo Kankasa, Nicolas Nagot, Nicolas Meda, James K Tumwine, Anna Coutsoudis, Thorkild Tylleskär, Hoosen Coovadia
Journal: BMJ (2017)

<b>Philippe Van de Perre and colleagues</b> say current strategies for preventing transmission of HIV infection from mother to child are inadequate and call for infants to be given pre-exposure prophylaxis
NCI pilot intervention program to assist accrual for challenging late-phase clinical trials.
Authors: Andrea Denicoff, Holly A Massett, Erin Souhan, Lynn Cave, John J. Welch, Nita Seibel, Richard F. Little, Bhupinder Singh Mann, Kate DiPiazza, Megan K. Rossmann, Sharon Hartson Stine, Ruth Lambersky, Frank DeSanto, Frances Fonzi, Deborah Schrag, Ross A. Abrams, David J. Adelstein, Paul D. Brown, Margaret M. Mooney, Jeffrey S. Abrams
Journal: Journal of Clinical Oncology (2014)

6617 Background: Since 2010, the National Cancer Institute (NCI) has taken substantial efforts to compress the timelines for protocol review and trial activation (Abrams, JNCI, 2013). In 2012, NCI’s Cancer Therapy Evaluation Program (CTEP) began a pilot in collaboration with NCI Cooperative Groups (CG) to support accrual to Phase 2-3 treatment trials identified as potentially challenging or at risk for insufficient accrual (Korn, JCO, 2010). Pilot program findings are reported. Methods: CG trials were identified for the pilot if accrual concerns were raised during the concept or protocol review or were at risk of not meeting CTEP’s slow accrual guidelines after activation. In collaboration with CG study teams, each trial underwent the following evaluation and analyses: accrual feasibility/challenges; site activation data; tailored interventions to address challenges, track and report accrual changes. Results: To date, 18 trials are in the pilot (10 identified pre-activation, 8 post-activation). Nine received interventions and 9 are in process. Interventions included: trial-specific materials, outreach to investigators/sites, survey data to guide amendments, social media outreach. Accrual data are available for 5 trial interventions. Quarterly accrual rates (QAR) increased for all 4 post-activation trials: Trial 1 now exceeds projected QAR (18 patients) by 6% (pre-intervention=10; post=19); Trial 2 exceeds projected QAR (72 pts) by 6% (pre=52; post=76); projected QAR for Trial 3 (36 pts) and Trial 4 (84 pts) remain below goals but QAR did improve(Trial 3: pre=5, post=29; Trial 4: pre=44, post=63). The lone pre-activation trial (Trial 5) is 61% below its projected QAR (102) 2 yrs after activating. Conclusions: Improved QARs for 4 of 5 trials. No intervention appears generally applicable and most trials require very specific interventions. Monitoring of trials will continue as interventions are implemented. CTEP plans to expand the pilot to support the new NCI National Clinical Trials Network (NCTN) and Early Therapeutic Clinical Trials Network (ET-CTN) and assist both early and late phase trials with accrual challenges. The effect of future interventions will be continually assessed.
Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
Authors: Graham H Jackson, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R Jones, Bhuvan Kishore, Mamta Garg, Cathy D Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew W Jenner, Gordon Cook, Martin F Kaiser, Mark T Drayson, Roger G Owen, Nigel H Russell, Walter M Gregory, Gareth J Morgan
Journal: Blood (2016)
Risk factors for inadequate bowel preparation: a validated predictive score
Authors: Antonio Gimeno-García, Jose Baute, Goretti Hernandez, Dalia Morales, Carmen Gonzalez-Pérez, David Nicolás-Pérez, Onofre Alarcon-Fernández, Alejandro Jiménez, Manuel Hernandez-Guerra, Rafael Romero, Inmaculada Alonso, Yanira Gonzalez, Zaida Adrian, Marta Carrillo, Laura Ramos, Enrique Quintero
Journal: Endoscopy (2017)

Background and study aim Inadequate bowel cleansing negatively affects the efficiency of colonoscopy in routine clinical practice. The aim of this study was to design and validate a predictive model for inadequate bowel cleanliness. Patients and methods The model was built from 667 consecutive outpatients (development cohort) who were prospectively scheduled for colonoscopy between June and September 2014. The validation cohort included 409 outpatients who underwent colonoscopy between October and December 2014. Cleansing was evaluated using the Boston Bowel Preparation Scale (BBPS). Bowel preparation was administered on the same day as the examination. Results In the development cohort, BBPS was adequate in 541 patients (81.1 %). At multivariate analysis, antidepressants (odds ratio [OR] 4.25, 95 % confidence interval [CI] 1.91 - 9.47), co-morbidity (OR 3.35, 95 %CI 2.16 - 5.18), constipation (OR 2.09, 95 %CI 1.29 - 3.40), and abdominal/pelvic surgery (OR 1.60, 95 %CI 1.03 - 2.47) were independent predictors for inadequate cleansing. The model built with these variables showed an area under the curve of 0.72 in the development cohort and 0.70 in the validation cohort. A cutoff of 1.225 predicted inadequate bowel preparation with a sensitivity, specificity, positive predictive value, and negative predictive value of 60.3 % (95 %CI 51.6 - 68.4), 75.4 % (95 %CI 71.6 - 78.9), 36.4 % (95 %CI 30.1 - 43.1), and 89.1 % (95 %CI 85.9 - 91.6) in the development cohort, and 50.0 % (95 %CI 38.1 - 61.9), 80.0 % (95 %CI 75.3 - 84.2), 35.7 % (95 %CI 26.4 - 45.6), and 87.9 % (95 %CI 83.7 - 91.3) in the validation cohort. Conclusion A simple score may assist the clinician in predicting which patients are at high risk of inadequate bowel cleanliness. This may guide changes in bowel preparation strategy accordingly.
Challenging Problems in Advanced Malignancy
Authors: Manuel F. Rosado, Elio Donna, Yeon S. Ahn
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.03.037 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12915610 Challenging Problems in Advanced Malignancy CASE 3. IMATINIB MESYLATE–INDUCED INTERSTITIAL PNEUMONITIS Manuel F. RosadoxManuel F. RosadoSearch for articles by this author , Elio DonnaxElio DonnaSearch for articles by this author , Yeon S. AhnxYeon S. AhnSearch for articles by this author Show More Sylvester Cancer Center, Miami, FL https://doi.org/10.1200/JCO.2003.03.037 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool
Authors: Rushad Patell, Lisa Rybicki, Keith R. McCrae, Alok A. Khorana
Journal: American Journal of Hematology (2017)

Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer varies and prophylaxis is inconsistently used. A previously validated tool (Khorana Score, [KS]) identifies VTE risk in cancer outpatients with 5 easily available variables but has not been studied in the inpatient setting. We evaluated the validity of KS in predicting VTE risk in hospitalized cancer patients. We conducted a retrospective cohort study of consecutive oncology inpatients at the Cleveland Clinic from 11/2012 to 12/2014 (n = 3531). Patients were excluded for VTE on admission (n = 304), incomplete KS data (n = 439) or other reasons (n = 8). Data collected included demographics, cancer type, length of stay (LOS), anticoagulant use, and laboratory values. Multivariate risk factors were identified with stepwise logistic regression, confirmed with bootstrap analysis. Of 2780 patients included, 106 (3.8%) developed VTE during hospitalization. Median age was 62 (range, 19-98) years and 56% were male. Median LOS was 5 (range, 0-152) days. High risk KS (≥ 3) was significantly associated with VTE in uni- and multivariate analyses (OR 2.5, 95% [confidence interval] CI 1.3-4.9). Other significant variables included male gender (OR 1.67, 1.1-2.53), older age (OR 0.86, 0.75-0.99) and use of anticoagulants (OR 0.57, 0.39-0.85). Recursive partitioning analysis suggested optimal cut point for KS is 2 (OR 1.82, 1.23-2.69). This is the first report validating KS as a risk tool to predict VTE in hospitalized cancer patients. Using this tool could lead to more consistent and successful application of inpatient thromboprophylaxis.
Stepwise Evolution of a Buried Inhibitor Peptide over 45 My
Authors: Achala S. Jayasena, Mark F. Fisher, Jose L. Panero, David Secco, Kalia Bernath-Levin, Oliver Berkowitz, Nicolas L. Taylor, Edward E. Schilling, James Whelan, Joshua S. Mylne
Journal: Molecular Biology and Evolution (2017)

The de novo evolution of genes and the novel proteins they encode has stimulated much interest in the contribution such innovations make to the diversity of life. Most research on this de novo evolution focuses on transcripts, so studies on the biochemical steps that can enable completely new proteins to evolve and the time required to do so have been lacking. Sunflower Preproalbumin with SFTI-1 (PawS1) is an unusual albumin precursor because in addition to producing albumin it also yields a potent, bicyclic protease-inhibitor called SunFlower Trypsin Inhibitor-1 (SFTI-1). Here, we show how this inhibitor peptide evolved stepwise over tens of millions of years. To trace the origin of the inhibitor peptide SFTI-1, we assembled seed transcriptomes for 110 sunflower relatives whose evolution could be resolved by a chronogram, which allowed dates to be estimated for the various stages of molecular evolution. A genetic insertion event in an albumin precursor gene ∼45 Ma introduced two additional cleavage sites for protein maturation and conferred duality upon PawS1-Like genes such that they also encode a small buried macrocycle. Expansion of this region, including two Cys residues, enlarged the peptide ∼34 Ma and made the buried peptides bicyclic. Functional specialization into a protease inhibitor occurred ∼23 Ma. These findings document the evolution of a novel peptide inside a benign region of a pre-existing protein. We illustrate how a novel peptide can evolve without de novo gene evolution and, critically, without affecting the function of what becomes the protein host.
Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia
Authors: Joseph A. Fraietta, Simon F. Lacey, Nicholas S Wilcox, Felipe Bedoya, Fang Chen, Elena Orlando, Jennifer L Brogdon, Wei-Ting Hwang, Noelle Frey, Regina M Young, Edward Pequignot, David E Ambrose, Bruce L Levine, Hans Bitter, David L Porter, Jun Xu, Carl H June, Jan Joseph Melenhorst
Journal: Blood (2016)
Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors
Authors: Mauricette Michallet, Mohamad Sobh, Fiorenza Barraco, Xavier Thomas, Marie Balsat, Caroline Lejeune, Sophie Ducastelle, Myriam Renault, Nathalie Tedone, Helene Labussiere, Franck-Emmanuel Nicolini
Journal: Blood (2016)
Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
Authors: Natalie Charnley, Alison J. Birtle, Ric Swindell, Omi Parikh, Marcus Wise+, Varadarajan Kumar, Falalu DAHIRU Danwata, Catherine Thompson
Journal: Journal of Clinical Oncology (2014)

e16054 Background: Abiraterone acetate is an androgen biosynthesis inhibitor which has shown response in patients with mCRPC treated prior to docetaxel chemotherapy ( Raj et al New Eng J med 2013). Prognostic factors have limited data. Methods: Retrospective review was undertaken of patients with mCRPC treated with abiraterone 1g daily pre-chemotherapy. Response was defined as > 50% reduction in PSA. PFS and OS were assessed. Established prognostic factors in mCRPC were explored. Results: 93 patients were identified. Median age was 73 years (55-90). Treatment was discontinued in 3/93 patients due to diarrhoea, one permanently. Dose reductions to 500mg od were seen in 2/93 (1: hypertension; 1 skin reaction) with biochemical response maintained. 42 /86 (49%) assessable patients had a PSA response to abiraterone ≥50% 44/86 (51%) patients have not yet progressed Median PFS is 208 days (95% CI 135-281) 18/93 patients have died. Median survival is not reached. Median 1 year survival is 76.2% (95% CI 86.6 - 65.8) On multivariate analysis albumin (alb)<35 was associated with reduced overall survival (p=0.01). Median 1 year survival for patients with alb>35 (n=79) or <35 (n=10) was 77.7% (95% CI 66.5-88.9), vs 54.9% (95% CI 21.2-88.6). For PSA response ≥50%, Hemoglobin (Hb) >11 was an independent prognostic variable (p=0.04). Response rates for patients with Hb≥11 and <11 were 54.7% and 27.3% respectively. On univariate analysis, prognostic factors for lack of biochemical response include PSA doubling time <55 days (p=0.03) and PS ≥2 (p=0.04). Other prognostic factors for OS were Hb<11 (p=0.00008), PSA doubling time <55 days (0.0002), Alkaline phosphatase (ALP) >1.5 upper limit normal (p=0.004), ALP>350 (p=0.002), visceral metastases (p=0.002), ≥2 metastatic sites (p=0.05), PS≥2 (p=0.000009), and duration of response to LHRH analogue <2 vs >4 years (p=0.03). Prognostic factors for reduced PFS are duration of response to LHRH analogue <2 vs >4 years (p=0.01), Hb<11 (p=0.002), ALP>1.5 ULN (p=0.0009) , and PS≥2 (p=0.03). Conclusions: In this cohort of 93 patients, Alb <35and Hb<11 are independently associated with OS and PSA response respectively. Validation in larger cohort is planned.